Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
An Observational Study of Peginterferon Alfa-2a (PEGASYS®) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B
- Conditions
- Hepatitis B, Chronic
- Interventions
- Biological: Peginterferon alfa-2a
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 141
- Registration Number
- NCT01667432
- Locations
- 🇧🇬
Mhat - Pleven; Clinic of Gastroenterology, Pleven, Bulgaria
🇧🇬Umhat St. Georgi; Clinical of Gastroenterology, Plovdiv, Bulgaria
🇧🇬MHAT Tokuda Hospital Sofia; Department of Gastroenterology at Clinic of Internal Deseases, Sofia, Bulgaria
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT01667471
An Observational Study of Mircera in Patients With Chronic Renal Anemia on Dialysis (CKD Stage V) or Not on Dialysis (CKD Stage III-IV)
- Conditions
- Anemia
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 78
- Registration Number
- NCT01667380
A Molecular and Functional Brain Imaging Study in Individuals With Down Syndrome and Healthy Controls Following Single Dose RG1662
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2015-09-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 13
- Registration Number
- NCT01667367
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2012-08-17
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 375
- Registration Number
- NCT01667562
- Locations
- 🇷🇸
Clinical Center Nis; Clinic for pulmonary diseases Knez Selo, Nis, Serbia
🇷🇸Clinical Center Bezanijska Kosa; Oncology, Belgrade, Serbia
🇷🇸Clinic for Pulmonology, Clinical Center of Serbia, Belgrade, Serbia
A Study of the Relative Bioavailability of Single Dose RO4917838 and the Effect of Food in Healthy Volunteers
- First Posted Date
- 2012-08-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT01665976
A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis
- First Posted Date
- 2012-08-15
- Last Posted Date
- 2018-02-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT01665430
A Study of the Effect of Fluvoxamine on the Pharmacokinetics of RO4917523 in Healthy Volunteers
- First Posted Date
- 2012-08-15
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT01665404
An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 49
- Registration Number
- NCT01664598
A Study to Evaluate Tocilizumab Treatment in a Real-Life Setting
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 151
- Registration Number
- NCT01664104